Mechanistic insights into ASO-RNA complexation: Advancing antisense oligonucleotide design strategies
Artikel i vetenskaplig tidskrift, 2024

Oligonucleotide drugs, an emerging modulator class, hold promise for targeting previously undruggable biomacromolecules. To date, only 18 oligonucleotide drugs, including sought-after antisense oligonucleotides (ASOs) and splice-switching oligonucleotides, have approval from the U.S. Food and Drug Administration. These agents effectively bind mRNA, inducing degradation or modulating splicing. Current oligonucleotide drug design strategies prioritize full Watson-Crick base pair (bp) complementarity, overlooking mRNA target three-dimensional shapes. Given that mRNA conformational diversity can impact hybridization, incorporating mRNA key structural properties into the design may expedite ASO lead discovery. Using atomistic molecular dynamics simulations inspired by experimental data, we demonstrate the advantages of incorporating common triple bps into the design of ASOs targeting RNA hairpin motifs, which are highly accessible regions for interactions. By using an RNA pseudoknot modified into an ASO-hairpin complex, we investigate the effects of ASO length and hairpin loop mutations. Our findings suggest that ASO-mRNA complex stability is influenced by ASO length, number of common triple bps, and the dynamic accessibility of bases in the hairpin loop. Our study offers new mechanistic insights into ASO-mRNA complexation and underscores the value of pseudoknots in constructing training datasets for machine learning models aimed at designing novel ASO leads.

molecular recognition

RNA hairpin

antisense oligonucleotides

MT: Oligonucleotides: Therapies and Applications

molecular dynamics simulations

Författare

Johanna Hörberg

Institutionen för kemi, GU

Antonio Carlesso

Göteborgs universitet

Anna Reymer

Göteborgs universitet

Molecular Therapy - Nucleic Acids

2162-2531 (ISSN)

Vol. 35 4 102351

Ämneskategorier (SSIF 2025)

Molekylärbiologi

DOI

10.1016/j.omtn.2024.102351

Mer information

Senast uppdaterat

2025-05-20